DOCSLIB.ORG

Glycodelin: a New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer Marc A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glycodelin: a New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer Marc A Published OnlineFirst April 21, 2015; DOI: 10.1158/1078-0432.CCR-14-2464 Biology of Human Tumors Clinical Cancer Research Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer Marc A. Schneider1,2, Martin Granzow3, Arne Warth2,4, Philipp A. Schnabel5, Michael Thomas2,6, Felix J.F. Herth2,7, Hendrik Dienemann2,8, Thomas Muley1,2, and Michael Meister1,2 Abstract Purpose: In recent years, immune therapeutic strategies Results: Glycodelin mRNA expression was significantly elevat- against non–smallcelllungcancer(NSCLC)basedontis- ed in tumors (n ¼ 336) compared with matched normal tissue sue-derived biomarkers, for example PD1/PD-L1 (CD274), (P < 0.0001). Overall survival (OS) was significantly reduced in have evolved as novel and promising treatment options. NSCLC with high glycodelin mRNA levels in women but not in However, the crosstalk between tumor and immune cells is men. Glycodelin was detected in the sera of patients, and the levels poorly understood. Glycodelin (gene name PAEP), initially correlated with recurrence and metastatic disease. Knockdown of described in the context of pregnancy and trophoblastic glycodelin with siRNAs in NSCLC cell lines resulted in significant implantation, is a secreted immunosuppressive glycopro- upregulation of immune system modulatory factors such as tein with an as-of-yet largely unknown function in lung PDL1, CXCL5, CXCL16, MICA/B, and CD83 as well as prolifer- cancer. ation stimulators EDN1 and HBEGF. Furthermore, decreased Experimental Design: In this study, we characterized migration of tumor cells was observed. the expression and role of glycodelin in NSCLC through Conclusions: Altogether, the comprehensive characterization mRNA and protein expression analyses, functional knock- of glycodelin in NSCLC provides strong support for its use as a down experiments, and correlations with clinicopathologic biomarker with immune modulatory function. Clin Cancer Res; parameters. 21(15); 3529–40. Ó2015 AACR. Introduction To improve the poor survival of lung cancer patients, chemo- therapeutic treatments are progressively supplemented with pre- With approximately 1.6 million cases worldwide, lung cancer is cision therapy based on genetic analyses. Sequencing of lung the leading cause of cancer-related death (1). Historically, lung carcinoma demonstrated a high somatic mutation rate of TP53, cancer is divided into two groups: non–small cell lung cancer KRAS, and EGFR (3). First-line and second-line tyrosine kinase (NSCLC), which accounts for more than 80% of all cases, and inhibitors that target the EGFR or anaplastic lymphoma kinase small-cell lung cancer (SCLC; ref. 2). (ALK) improve progression-free survival (4–6). Surface markers and secreted chemokines of altered cells attract lymphocytes, natural killer cells (NK) or cytotoxic T cells. The tumor microenvironment is strongly defined by extracellular 1Translational Research Unit, Thoraxklinik at University Hospital Hei- matrix (ECM) reorganization and chemokine secretion of tumor delberg, Heidelberg, Germany. 2Translational Lung Research Center cells that leads to a barrier for lymphocytes (7). Infiltration of Heidelberg (TLRC-H), Member of the German Center for Lung NSCLCs with lymphocytes is associated with better disease-free Research (DZL), Heidelberg, Germany. 3Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany. 4Institute of Patholo- survival (8). Thus, immune therapy has the potential to stimulate gy, University of Heidelberg, Heidelberg, Germany. 5Institut fur€ Allge- the patient's immune system response and attack cancer cells meine und Spezielle Pathologie, University of the Saarland, Homburg/ more effectively. Manipulation of NK cells and natural killer T Saar, Germany. 6Department of Thoracic Oncology, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany. 7Department of cells (NKT) is considered to be a useful tool for cancer immuno- Pneumology and Critical Care Medicine, Thoraxklinik at University therapy (9, 10). 8 Hospital Heidelberg, Heidelberg, Germany. Department of Surgery, Glycodelin (gene name PAEP), initially described as placental Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany. protein 14 (PP14) or progesterone-associated endometrial pro- Note: Supplementary data for this article are available at Clinical Cancer tein (PAEP), is strongly associated with trophoblastic invasiveness Research Online (http://clincancerres.aacrjournals.org/). (11). Downregulation of glycodelin leads to an increased activa- Corresponding Author: Michael Meister, Thoraxklinik at University Hospital Hei- tion of the maternal immune system and can result in abortion delberg, Amalienstrasse 5, Heidelberg 69126, Germany. Phone: 49-6221-396-1650; during the first trimester (12). Glycodelin is differentially glyco- Fax: 49-6221-396-1652; E-mail: [email protected] sylated depending on gender and function (13). Glycodelin A, the doi: 10.1158/1078-0432.CCR-14-2464 immunosuppressive form of glycodelin, functions as a prolifer- Ó2015 American Association for Cancer Research. ation-suppressor and apoptosis inducer of T cells, monocytes, B www.aacrjournals.org 3529 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2015 American Association for Cancer Research. Published OnlineFirst April 21, 2015; DOI: 10.1158/1078-0432.CCR-14-2464 Schneider et al. trol siRNA-transfected and PAEP siRNA pool-transfected samples Translational Relevance per cell line. Detailed descriptions are provided in the Supple- Glycodelin is well described as an immune system mod- mentary Materials and Methods. ulator during pregnancy. In this work, we demonstrate the – expression and secretion of glycodelin in non small cell lung Quantitative Real-Time PCR cancer (NSCLC), its potential role as an immune system Real-time quantitative PCR (qPCR) was performed in accor- modulator, and the feasibility of using glycodelin as a bio- dance with MIQE-guidelines (19) using a LightCycler 480 Real- PAEP marker for NSCLC. Glycodelin mRNA (gene name ) was Time PCR Instrument in a 384-well plate format (Roche). Gene- overexpressed in approximately 80% of all tumors compared specific primers and probes (Universal ProbeLibrary; Roche) were PAEP with normal tissue. Knockdown of resulted in a dereg- used in combination with ABsolute QPCR Mix (Thermo Scien- ulation of immune system modulators, for example, PD-L1, a tific). Ct values were calculated with LightCycler 480 software current immune therapeutic target. We demonstrate the detec- version 1.5 using the second derivative maximum method tion of glycodelin in tissues and sera of NSCLC patients. The (Roche). Detailed descriptions are provided in the Supplementary fact that the glycodelin serum levels correlated with the Materials and Methods. patients' response to treatment suggests its use as a biomarker for follow-up of NSCLC. A diagnostic tool for glycodelin quantification in pregnancy is commercially available and Immunohistochemistry might be conveniently for use in lung cancer diagnoses. To compare the expression of whole glycodelin and glycodelin A, the polyclonal N-20 antibody (sc-12289, Santa Cruz Biotech- nology) and the monoclonal A87-B/D2 (Glycotope) antibody, raised against glycodelin A purified from mid-trimester amniotic fluid, were used. Detailed descriptions are provided in the Sup- cells and NK cells (14). Atypical glycodelin expression is observed plementary Materials and Methods. in hormone-related breast cancer, endometrial cancer, and ovar- ian cancer (15). Recent studies have demonstrated glycodelin Detection of glycodelin in human sera expression in melanoma cells and lung cancer (16, 17). Gene- Human sera were collected before any disease-specific treat- PAEP expression data from our group revealed that is expressed in ment and stored at À80C within 2 hours after venipuncture. The a lung cancer cell line as well (18). NSCLC validation cohort included pretherapeutic sera of 159 To elucidate the role of glycodelin in NSCLC, we comprehen- randomly selected NSCLC patients (clinical stage I–IV). The sively analyzed its expression in resection specimens as well as its chronic obstructive pulmonary disease (COPD) control cohort function in cell culture-based experiments. Furthermore, expres- included 90 randomly selected sera of COPD I–IV patients. The sion data were correlated with clinical data, including patient glycodelin levels of the sera were detected using an enzyme-linked outcomes. We demonstrate that glycodelin is highly expressed in immunosorbent assay kit (ELISA BS-20-30; Bioserv Diagnostics) fi NSCLC. It regulates tumor cell expression pro les to undergo with 50 mL of each serum in two technical replicates. The readout immune system defense and can be used as a biomarker to track and standard curve were performed with ELISA Reader (Tecan tumor progression, recurrence, or metastatic spread. Group Ltd.). The results of ELISA were visualized with GraphPad Prism 5. Detailed descriptions are provided in the Supplementary Materials and Methods Materials and Methods. Tissue sample collection, characterization, and preparation Tissue samples were provided by Lung Biobank Heidelberg, a Statistical analyses member of the accredited Tissue Bank of the National Center for Data of qPCR analyses were statistically analyzed under Tumor Diseases (NCT) Heidelberg, the BioMaterialBank Heidel- REMARK criteria (20) with SPSS 22.0 for Windows (IBM). The berg and the Biobank platform of the German Center for Lung
Load more

Recommended publications
  • Characteristic Changes in Decidual Gene Expression Signature in Spontaneous Term Parturition
    Journal of Pathology and Translational Medicine 2017; 51: 264-283 ▒ ORIGINAL ARTICLE ▒ https://doi.org/10.4132/jptm.2016.12.20 Characteristic Changes in Decidual Gene Expression Signature in Spontaneous Term Parturition Haidy El-Azzamy1,* · Andrea Balogh1,2,* Background: The decidua has been implicated in the “terminal pathway” of human term parturi- Roberto Romero1,3,4,5 · Yi Xu1 tion, which is characterized by the activation of pro-inflammatory pathways in gestational tissues. Christopher LaJeunesse1 · Olesya Plazyo1 However, the transcriptomic changes in the decidua leading to terminal pathway activation have Zhonghui Xu1 · Theodore G. Price1 not been systematically explored. This study aimed to compare the decidual expression of devel- Zhong Dong1 · Adi L. Tarca1,6 opmental signaling and inflammation-related genes before and after spontaneous term labor in Zoltan Papp7 · Sonia S. Hassan1,6 order to reveal their involvement in this process. Methods: Chorioamniotic membranes were 1,6 Tinnakorn Chaiworapongsa obtained from normal pregnant women who delivered at term with spontaneous labor (TIL, n = 14) 1,8,9 Chong Jai Kim or without labor (TNL, n = 15). Decidual cells were isolated from snap-frozen chorioamniotic mem- Nardhy Gomez-Lopez1,6 branes with laser microdissection. The expression of 46 genes involved in decidual development, Nandor Gabor Than1,6,7,10,11 sex steroid and prostaglandin signaling, as well as pro- and anti-inflammatory pathways, was ana- lyzed using high-throughput quantitative real-time polymerase chain reaction (qRT-PCR). Chorio- 1Perinatology Research Branch, NICHD/NIH/DHHS, amniotic membrane sections were immunostained and then semi-quantified for five proteins, and Bethesda, MD, and Detroit, MI, USA; 2Department of Immunology, Eotvos Lorand University, Budapest, immunoassays for three chemokines were performed on maternal plasma samples.
    [Show full text]
  • 2021 Undergraduate Research Abstract Booklet
    1 | P a g e Table of Contents FOREWORD ................................................................................................................................................... 4 Abidemi Awojuyigbe ..................................................................................................................................... 5 Aijalon Shantavia........................................................................................................................................... 6 Aminata Diagne ............................................................................................................................................. 8 The Exploration of BRAF Gene .................................................................................................................... 10 Araceli Estrada Martinez ............................................................................................................................. 10 Ashlee Young ............................................................................................................................................... 11 Ayanna D. Montegut ................................................................................................................................... 12 Brandon Bernäl ........................................................................................................................................... 13 Caleb Riggins ..............................................................................................................................................
    [Show full text]
  • Unravelling Genetic Variation Underlying De Novo-Synthesis Of
    www.nature.com/scientificreports OPEN Unravelling genetic variation underlying de novo-synthesis of bovine milk fatty acids Received: 18 July 2017 Tim Martin Knutsen1, Hanne Gro Olsen1, Valeria Tafntseva2, Morten Svendsen3, Accepted: 18 January 2018 Achim Kohler2, Matthew Peter Kent1 & Sigbjørn Lien1 Published: xx xx xxxx The relative abundance of specifc fatty acids in milk can be important for consumer health and manufacturing properties of dairy products. Understanding of genes controlling milk fat synthesis may contribute to the development of dairy products with high quality and nutritional value. This study aims to identify key genes and genetic variants afecting de novo synthesis of the short- and medium- chained fatty acids C4:0 to C14:0. A genome-wide association study using 609,361 SNP markers and 1,811 animals was performed to detect genomic regions afecting fatty acid levels. These regions were further refned using sequencing data to impute millions of additional genetic variants. Results suggest associations of PAEP with the content of C4:0, AACS with the content of fatty acids C4:0-C6:0, NCOA6 or ACSS2 with the longer chain fatty acids C6:0-C14:0, and FASN mainly associated with content of C14:0. None of the top-ranking markers caused amino acid shifts but were mostly situated in putatively regulating regions and suggested a regulatory role of the QTLs. Sequencing mRNA from bovine milk confrmed the expression of all candidate genes which, combined with knowledge of their roles in fat biosynthesis, supports their potential role in de novo synthesis of bovine milk fatty acids. Bovine milk is an important source of many nutrients including proteins, fat, minerals, vitamins and bioactive lipid components.
    [Show full text]
  • PAEP Antibody Cat
    PAEP Antibody Cat. No.: 57-832 PAEP Antibody PAEP Antibody immunohistochemistry analysis in formalin fixed and paraffin embedded human uterus tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human This PAEP antibody is generated from rabbits immunized with a KLH conjugated synthetic IMMUNOGEN: peptide between 73-101 amino acids from the Central region of human PAEP. TESTED APPLICATIONS: IHC-P, WB For WB starting dilution is: 1:1000 APPLICATIONS: For IHC-P starting dilution is: 1:10~50 PREDICTED MOLECULAR 21 kDa WEIGHT: September 30, 2021 1 https://www.prosci-inc.com/paep-antibody-57-832.html Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: PAEP Glycodelin, GD, Placental protein 14, PP14, Pregnancy-associated endometrial alpha-2 ALTERNATE NAMES: globulin, PAEG, PEG, Progestagen-associated endometrial protein, Progesterone- associated endometrial protein, PAEP ACCESSION NO.: P09466 PROTEIN GI NO.: 130701 GENE ID: 5047 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References This gene is a member of the kernel lipocalin superfamily whose members share relatively low sequence similarity but have highly conserved exon/intron structure and three- dimensional protein folding.
    [Show full text]
  • Development of a Proteomic Assay for Menstrual Blood, Vaginal Fluid and Species Identification Author(S): Donald Siegel, Ph.D
    The author(s) shown below used Federal funding provided by the U.S. Department of Justice to prepare the following resource: Document Title: Development of a Proteomic Assay for Menstrual Blood, Vaginal Fluid and Species Identification Author(s): Donald Siegel, Ph.D. Document Number: 251932 Date Received: August 2018 Award Number: 2010-DN-BX-K192 This resource has not been published by the U.S. Department of Justice. This resource is being made publically available through the Office of Justice Programs’ National Criminal Justice Reference Service. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Development of a Proteomic Assay for Menstrual Blood, Vaginal Fluid and Species Identification Final Draft Technical Report NIJ Grant 2010-DN-BX-K192 Principal Investigator: Donald Siegel, Ph.D. Principal Scientist Office of Chief Medical Examiner 421 East 26th Street New York, NY 10016 Tel: 212-323-1434 Fax: 212-323-1560 Email: [email protected] Web: www.nyc.gov/ocme This resource was prepared by the author(s) using Federal funds provided by the U.S. Department of Justice. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Final Draft Technical Report NIJ Grant 2010-DN-BX-K192 Development of a Proteomic Assay for Menstrual Blood, Vaginal Fluid and Species Identification TABLE OF CONTENTS ABBREVIATIONS……………………………………………………………………………………………………………………..4
    [Show full text]
  • Genomics of Bovine Milk Fat Composition
    Philosophiae Doctor (PhD), Thesis 2018:19 (PhD), Doctor Philosophiae Norwegian University of Life Sciences Faculty of Biosciences Philosophiae Doctor (PhD) Thesis 2018:19 Tim Martin Tim Knutsen Genomics of bovine milk fat composition Genetisk karakterisering av fettsyresammensetning i melk Tim Martin Knutsen !" # $ % &%' " ()*+, - )*+,.+/ 0""+,/1231*) 0"$/4,2,)25452+1//2* 2 Acknowledgements The work presented here has been part of the project “Genome-based improvement of bovine milk fatty acids”. The project was coordinated by the Norwegian University of Life Sciences (NMBU) and was a collaboration between NMBU, GENO SA and TINE SA. The project was funded by The Norwegian Research Council. To my dear supervisors. Sigbjørn, you are constantly supportive, work relentlessly for what you believe in, and it has been an honour to learn from you. Hanne Gro, thanks for the endless hours we have spent discussing this project, your critical sense, and your treasured help in the writing process. Torfinn, thanks for your out-of-this-world-value-for-money bioinformatics coaching and advice. And Matthew, thanks for all your hours polishing my writing, your enthusiasm for cool sequencing technologies and your wonderful sense of humour. My sincere thanks to all others who have contributed to this work, especially Achim Kohler, Valeria Tafinseva and Morten Svendsen for enabling the fatty acid GWAS with your mathematical wizardry. I also want to express my gratitude to Arne Gvusland for your critical comments to an early draft of this thesis, and for time after time dragging me out to jog at times when I really needed it. Seven years ago, late for my appointment, I stumbled into Sigbjørn’s office to discuss possible master projects.
    [Show full text]
  • Serum Biomarkers of Tubal Ectopic Pregnancy: Current Candidates and Future Possibilities
    REPRODUCTIONREVIEW Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities Joanna Cartwright, W Colin Duncan, Hilary O D Critchley and Andrew W Horne Division of Reproductive and Developmental Sciences, Simpson Centre for Reproductive Health, The University of Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SB, UK Correspondence should be addressed to A W Horne; Email: [email protected] Abstract Ectopic pregnancy remains a considerable cause of maternal morbidity and mortality worldwide. Currently, it is diagnosed using a combination of transvaginal ultrasound and serial serum b-human chorionic gonadotrophin levels. Diagnosis is often delayed and these tests are time-consuming and costly, both psychologically to the patient and financially to health services. The development of a biomarker that can differentiate a tubal ectopic from an intrauterine implantation is therefore important. In the pre-genomic era, a one-by-one scientific approach has revealed over 20 candidate biomarkers that could be used as a test to diagnose ectopic pregnancy although at present their clinical utility is very limited. These biomarkers cluster into themes: markers of abnormal embryo/trophoblast growth, markers of abnormal corpus luteum function, markers of a growing pregnancy in the Fallopian tube, markers of inflammation and peritoneal irritation, and uterine markers of normal implantation. It is likely that this thematic approach will facilitate the identification of newer biomarkers using
    [Show full text]
  • Recurrent Pregnancy Loss Is Associated with a Pro-Senescent Decidual Response During the Peri-Implantation Window Emma S Lucas1
    bioRxiv preprint doi: https://doi.org/10.1101/368829; this version posted December 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Recurrent pregnancy loss is associated with a pro-senescent decidual response during 2 the peri-implantation window 3 4 Emma S Lucas1,2†, Pavle Vrljicak1,2†, Joanne Muter1,2 , Maria M Diniz-da-Costa1,2, Paul J 5 Brighton2, Chow-Seng Kong2, Julia Lipecki3, Katherine Fishwick2, Joshua Odendaal2, Lauren 6 J. Ewington2, Siobhan Quenby1,2, Sascha Ott1,4, and Jan J Brosens1,2,* 7 8 1Tommy’s National Centre for Miscarriage Research, University Hospitals Coventry & 9 Warwickshire, Coventry, CV2 2DX, United Kingdom. 10 2Division of Biomedical Sciences, Clinical Sciences Research Laboratories, Warwick Medical 11 School, University of Warwick, Coventry CV2 2DX, United Kingdom. 12 3School of Life Sciences, Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, 13 United Kingdom. 14 4Department of Computer Science, University of Warwick, Coventry, CV4 7AL, United 15 Kingdom. 16 *Corresponding Author and Lead Contact: Jan Brosens M.D., Ph.D. Clinical Sciences 17 Research Laboratories, Warwick Medical School, University of Warwick, Coventry CV2 2DX, 18 United Kingdom. Tel: +44 2476968704; FAX: +44 2476968653; Email: 19 [email protected] 20 †These authors contributed equally 1 bioRxiv preprint doi: https://doi.org/10.1101/368829; this version posted December 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Signatures of Adaptive Evolution in Platyrrhine Primate Genomes 5 6 Hazel Byrne*, Timothy H
    1 2 Supplementary Materials for 3 4 Signatures of adaptive evolution in platyrrhine primate genomes 5 6 Hazel Byrne*, Timothy H. Webster, Sarah F. Brosnan, Patrícia Izar, Jessica W. Lynch 7 *Corresponding author. Email [email protected] 8 9 10 This PDF file includes: 11 Section 1: Extended methods & results: Robust capuchin reference genome 12 Section 2: Extended methods & results: Signatures of selection in platyrrhine genomes 13 Section 3: Extended results: Robust capuchins (Sapajus; H1) positive selection results 14 Section 4: Extended results: Gracile capuchins (Cebus; H2) positive selection results 15 Section 5: Extended results: Ancestral Cebinae (H3) positive selection results 16 Section 6: Extended results: Across-capuchins (H3a) positive selection results 17 Section 7: Extended results: Ancestral Cebidae (H4) positive selection results 18 Section 8: Extended results: Squirrel monkeys (Saimiri; H5) positive selection results 19 Figs. S1 to S3 20 Tables S1–S3, S5–S7, S10, and S23 21 References (94 to 172) 22 23 Other Supplementary Materials for this manuscript include the following: 24 Tables S4, S8, S9, S11–S22, and S24–S44 1 25 1) Extended methods & results: Robust capuchin reference genome 26 1.1 Genome assembly: versions and accessions 27 The version of the genome assembly used in this study, Sape_Mango_1.0, was uploaded to a 28 Zenodo repository (see data availability). An assembly (Sape_Mango_1.1) with minor 29 modifications including the removal of two short scaffolds and the addition of the mitochondrial 30 genome assembly was uploaded to NCBI under the accession JAGHVQ. The BioProject and 31 BioSample NCBI accessions for this project and sample (Mango) are PRJNA717806 and 32 SAMN18511585.
    [Show full text]
  • Development of New Mrna Markers for the Identification of Menstrual Blood
    Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 48, no. 1, 2018 55 Development of New mRNA Markers for the Identification of Menstrual Blood Qiong Liang1, Hongyu Sun2, Xinyao Wu2, Xueling Ou2, Guoquan Gao3, Yi Jin1, and Dayue Tong2 1Department of Pathology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 2Forensic Biology Section, Sun Yat-Sen University, Guangzhou, and 3Department of Biochemistry and Molecular Biology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China Abstract. Background. The aim of this study was to screen 3 mRNA markers (i.e., PAEP, LAPR3, and HOXA10) with diverse expression in different body fluids and to develop a method for the identification of menstrual blood using these mRNA markers. Methods. Body fluid (i.e., venous blood, menstrual blood, semen, and saliva) samples were collected and prepared under differing environmental conditions (tem- perature, humidity and time), and RNA was extracted and reverse transcribed. The expression specificity of these markers was assessed using TaqMan probe qPCR. Results. A high mean cycle threshold value cor- responds to a lower expression level. The mean cycle threshold value of the LAPR3, HOXA10, and PAEP genes are 8.37, 8.73, 4.67 in menstrual blood respectively. LAPR3 and PAEP were only expressed in men- strual blood. HOXA10 were expressed in blood, menstrual blood, and semen. No significant differences were found while the mean cycle threshold of MMP11 and PAEP were compared in the menstrual blood under common environmental conditions. There were no observed differences in the expression of the tar- get genes in women of different ages and at different menstrual phases.
    [Show full text]
  • CXCL12 Enhances Pregnancy Outcome Via Improvement Of
    www.nature.com/scientificreports OPEN CXCL12 enhances pregnancy outcome via improvement of endometrial receptivity in mice Hwa Seon Koo1, Min‑Ji Yoon2, Seon‑Hwa Hong1, Jungho Ahn2, Hwijae Cha2, Danbi Lee2, Ji‑Eun Ko1, Hwang Kwon1, Dong Hee Choi1, Kyung‑Ah Lee2, Jung‑Jae Ko2 & Youn‑Jung Kang1,2,3* Successful pregnancy inevitably depends on the implantation of a competent embryo into a receptive endometrium. Although many substances have been suggested to improve the rate of embryo implantation targeting enhancement of endometrial receptivity, currently there rarely are efective evidence‑based treatments to prevent or cure this condition. Here we strongly suggest minimally‑invasive intra‑uterine administration of embryo‑secreted chemokine CXCL12 as an efective therapeutic intervention. Chemokine CXCL12 derived from pre‑ and peri‑implanting embryos signifcantly enhances the rates of embryo attachment and promoted endothelial vessel formation and sprouting in vitro. Consistently, intra‑uterine CXCL12 administration in C57BL/6 mice improved endometrial receptivity showing increased integrin β3 and its ligand osteopontin, and induced endometrial angiogenesis displaying increased numbers of vessel formation near the lining of endometrial epithelial layer with higher CD31 and CD34 expression. Furthermore, intra‑uterine CXCL12 application dramatically promoted the rates of embryo implantation with no morphologically retarded embryos. Thus, our present study provides a novel evidence that improved uterine endometrial receptivity and enhanced angiogenesis induced by embryo‑derived chemokine CXCL12 may aid to develop a minimally‑invasive therapeutic strategy for clinical treatment or supplement for the patients with repeated implantation failure with less risk. Even though a remarkable improvement of assisted reproductive technology (ART) has been achieved for the last several decades, there are still a number of infertile women experiencing frequent ART failure afer repeated attempts due to many unsolved problems including repeated failure of implantation.
    [Show full text]
  • PAEP ELISA Kit Human (OKEH02065)
    PAEP ELISA Kit Human (OKEH02065) Instructions for Use For the quantitative measurement of PAEP in Human biological samples. This product is intended for research use only. v1.0 PAEP ELISA Kit (Human) (OKEH02065) v1.0 Table of Contents 1. Background ............................................................................................................................................. 2 2. Assay Summary ..................................................................................................................................... 3 3. Storage and Stability .............................................................................................................................. 3 4. Kit Components ...................................................................................................................................... 3 5. Precautions ............................................................................................................................................. 4 6. Required Materials Not Supplied ......................................................................................................... 4 7. Technical Application Tips .................................................................................................................... 4 8. Reagent Preparation .............................................................................................................................. 5 9. Sample Preparation Guidelines ..........................................................................................................
    [Show full text]